Abliva Future Growth

Future criteria checks 0/6

Abliva's earnings are forecast to decline at 17.6% per annum while its annual revenue is expected to grow at 137.1% per year. EPS is expected to decline by 7.3% per annum.

Key information

-17.6%

Earnings growth rate

-7.3%

EPS growth rate

Biotechs earnings growth	49.3%
Revenue growth rate	137.1%
Future return on equity	n/a
Analyst coverage	Low
Last updated	27 Aug 2024

Recent future growth updates

No updates

Recent updates

Earnings and Revenue Growth Forecasts

OM:ABLI - Analysts future estimates and past financials data (SEK Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	3	-161	-154	-153	1
12/31/2025	N/A	-141	-135	-134	1
12/31/2024	N/A	-119	-111	-110	1
6/30/2024	0	-102	-58	-57	N/A
3/31/2024	0	-98	-28	-27	N/A
12/31/2023	0	-96	-9	-8	N/A
9/30/2023	N/A	-88	-15	-15	N/A
6/30/2023	0	-80	-115	-114	N/A
3/31/2023	0	-79	-145	-144	N/A
12/31/2022	0	-85	-160	-160	N/A
9/30/2022	0	-105	-195	-194	N/A
6/30/2022	0	-114	-121	-120	N/A
3/31/2022	0	-124	-124	-123	N/A
12/31/2021	0	-123	-115	-114	N/A
9/30/2021	2	-100	-86	-84	N/A
6/30/2021	2	-75	-69	-68	N/A
3/31/2021	2	-65	-54	-53	N/A
12/31/2020	2	-60	-69	-68	N/A
9/30/2020	1	-74	-79	-77	N/A
6/30/2020	3	-79	-84	-82	N/A
3/31/2020	4	-80	-83	-80	N/A
12/31/2019	4	-77	-75	-72	N/A
9/30/2019	4	-65	-67	-63	N/A
6/30/2019	2	-64	-61	-57	N/A
3/31/2019	2	-69	-75	-72	N/A
12/31/2018	2	-68	-68	-64	N/A
9/30/2018	2	-68	-66	-62	N/A
6/30/2018	2	-66	-68	-64	N/A
3/31/2018	0	-63	N/A	-57	N/A
12/31/2017	0	-67	N/A	-58	N/A
9/30/2017	0	-66	N/A	-60	N/A
6/30/2017	0	-87	N/A	-55	N/A
3/31/2017	0	-76	N/A	-55	N/A
12/31/2016	0	-70	N/A	-57	N/A
9/30/2016	N/A	-63	N/A	-62	N/A
6/30/2016	N/A	-83	N/A	-66	N/A
3/31/2016	3	-87	N/A	-59	N/A
12/31/2015	3	-90	N/A	-67	N/A
9/30/2015	4	-100	N/A	-52	N/A
6/30/2015	11	-49	N/A	-50	N/A
3/31/2015	8	-47	N/A	-49	N/A
12/31/2014	8	-43	N/A	-44	N/A
9/30/2014	7	-35	N/A	-47	N/A
6/30/2014	1	-38	N/A	-41	N/A
3/31/2014	6	-27	N/A	-31	N/A
12/31/2013	7	-22	N/A	-19	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: ABLI is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: ABLI is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: ABLI is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: ABLI is forecast to have no revenue next year.

High Growth Revenue: ABLI is forecast to have no revenue next year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if ABLI's Return on Equity is forecast to be high in 3 years time

Abliva Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Recent updates

Is Abliva (STO:ABLI) In A Good Position To Invest In Growth?

New major risk - Shareholder dilution

New major risk - Financial position

Abliva AB (publ) Announces Positive Interim Analysis of the FALCON Study for KL1333 in Primary Mitochondrial Disease

Abliva AB (Publ) Announces Completion of 24 Weeks of Dosing in Wave 1 of the Falcon Study of KL1333 in Primary Mitochondrial Disease

New minor risk - Shareholder dilution

Abliva AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 46.093054 million.

Full year 2023 earnings released: kr0.09 loss per share (vs kr0.12 loss in FY 2022)

New minor risk - Share price stability

Abliva (STO:ABLI) Is In A Strong Position To Grow Its Business

Abliva AB (publ) to Report Nine Months, 2024 Results on Nov 21, 2024

Abliva AB (publ) to Report First Half, 2024 Results on Aug 22, 2024

Abliva AB (publ) Achieves Important Milestone in the Ongoing FALCON Study

Abliva AB (publ), Annual General Meeting, May 23, 2024

Here's Why We're A Bit Worried About Abliva's (STO:ABLI) Cash Burn Situation

Chairman of the Board recently bought kr494k worth of stock

Abliva AB (Publ) Announces First Patient Dosed in the Falcon Study

Abliva AB (Publ) Announces Resignation of Edwin Moses as Director

Abliva AB Initiates the Global Falcon Study with Lead Candidate KL1333

No independent directors

Abliva AB (publ), Annual General Meeting, Apr 27, 2023

Abliva AB (publ) to Report First Half, 2023 Results on Aug 18, 2023

Is Abliva (STO:ABLI) In A Good Position To Invest In Growth?

Director recently bought kr35m worth of stock

Abliva AB (publ) to Report Fiscal Year 2022 Results on Feb 24, 2023

No independent directors

Abliva AB (publ) to Report Fiscal Year 2021 Results on Apr 29, 2022

Abliva AB (publ) to Report Fiscal Year 2021 Results on Apr 29, 2022

Full year 2021 earnings: EPS misses analyst expectations

US Food and Drug Administration Approves Abliva's Investigational New Drug (IND) Application for KL1333

Third quarter 2021 earnings released: kr0.086 loss per share (vs kr0.03 loss in 3Q 2020)

We're Keeping An Eye On Abliva's (STO:ABLI) Cash Burn Rate

Abliva Reports Positive Clinical Phase 1A/B Results for KL1333 Including Signs of Efficacy in PMD Patients

Is Abliva (STO:ABLI) In A Good Position To Invest In Growth?

Abliva Completes Phase Ia/Ib Study with KL1333

Full year 2020 earnings released: kr0.24 loss per share (vs kr0.45 loss in FY 2019)

Revenue and earnings miss expectations

New 90-day low: kr0.74

Chief Executive Officer Erik Kinnmann has left the company

Abliva Announces CEO Changes, with Effect from February 3rd

New 90-day low: kr0.77

How Much Is Abliva AB (publ) (STO:ABLI) Paying Its CEO?

Third quarter 2020 earnings released: kr0.03 loss per share

Abliva AB (publ) to Report Fiscal Year 2021 Results on Feb 22, 2022

New 90-day low: kr0.78

New 90-day low: kr0.91

Abliva AB Announces Resignation of Magnus Persson From Board of Directors

Earnings released

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies